Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine

Anti-Cancer Drugs

Volumn 20, Issue 8, 2009, Pages 693-701

  Janus, Agnieszka ^a   Linke, Anna ^a   Cebula, Barbara ^a   Robak, Tadeusz ^a   Smolewski, Piotr ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Acute myeloid leukemia; MTOR kinase inhibitor; Rapamycin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 3; CYCLIN E; CYTARABINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; GROWTH REGULATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CASPASE 3; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CHROMONES; CYCLINS; CYTARABINE; DRUG SYNERGISM; ENZYME INHIBITORS; GENE EXPRESSION; HL-60 CELLS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEINS; PROTEIN KINASES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 70349322878     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32832e89b4     Document Type: Article

References (49)

1. Rice KL, Licht JD. HOX deregulation in acute myeloid leukemia. J Clin Invest 2007; 117:865-878.
2. Doepfner KT, Boller D, Arcaro A. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia. Crit Rev Oncol Hematol 2007; 63:215-230.
3. Frankfurt O, Licht JD, Tallman MS. Molecular characterization of acute myeloid leukemia and its impact on treatment. Curr Opin Oncol 2007; 19:635-649.
4. Haferlach T. Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. In: Hematology Am Soc Hematol Educ Program. American Society of Hematology; 2008. pp. 400-411.
5. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003; 102:972-980.
6. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4:335-348.
7. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35 (3 Suppl):7S-14S.
8. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005; 11:353-361.
9. Burnett AK, Knapper S. Targeting treatment in AML. In: Hematology Am Soc Hematol Educ Program. American Society of Hematology; 2007. pp. 429-434.
10. Fasolo A, Sessa C. mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 2008; 17:1717-1734.
11. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008; 8:393-412.
12. Hutson TE, Figlin RA. Experimental therapy for advanced renal cell carcinoma. Expert Opin Investig Drugs 2008; 17:1693-1702.
13. Lévy A, Sauvin LA, Massard C, Soria JC. Everolimus (RAD001) and solid tumours: a 2008 summary. Bull Cancer 2008; 95:1205-1211.
14. Baldo P, Cecco S, Giacomin E, Lazzarini R, Ros B, Marastoni S. mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug Targets 2008; 8:647-665.
15. Flaherty KT. The future of tyrosine kinase inhibitors: single agent or combination? Curr Oncol Rep 2008; 10:264-270.
16. Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008; 26:361-367. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01644.html
17. Rini BI. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res 2008; 14:1286-1290.
18. Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F. Deforolimus (AP 23573) a novel mTOR inhibitor in clinical development. Expert Opin Invest Drugs 2008; 17:1947-1954.
19. Delmonte A, Sessa C. Molecule-targeted agents in endometrial cancer. Curr Opin Oncol 2008; 20:554-559.
20. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449-456.
21. Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008; 14:2756-2762.
22. Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus(RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006; 12:5165-5173. (Pubitemid 44453345)
23. Schmidt C, Dreyling M. Therapy of mantle cell lymphoma: current standards and future strategies. Hematol Oncol Clin North Am 2008; 22:953-963.
24. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23:5314-5322.
25. Paoluzzi L, Kitagawa Y, Kalac M, Zain J, O'Connor OA. New drugs for the treatment of lymphoma. Hematol Oncol Clin North Am 2008; 22:1007-1035.
26. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004; 91:1420-1424.
27. Smolewski P. Investigating mammalian target of rapamycin inhibitors for their anticancer properties. Expert Opin Invest Drugs 2006; 15: 1201-1227.
28. Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 2006; 17:487-494.
29. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005; 55:178-194.
30. Dancey JE. Therapeutic targets: MTOR and related pathways. Cancer Biol Ther 2006; 5:1065-1073.
31. Grant S. Cotargeting survival signaling pathways in cancer. J Clin Invest 2008; 118:3051-3064.
32. Leung KT, Li KK, Sun SS, Chan PK, Ooi VE, Chiu LC. Activation of the JNK pathway promotes phosphorylation and degradation of BimEL-a novel mechanism of chemoresistance in T-cell acute lymphoblastic leukemia. Carcinogenesis 2008; 29:544-551.
33. Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F, et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003; 101:278-285.
34. Decker T, Sandherr M, Goetze K, Oelsner M, Ringshausen I, Peschel C. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann Hematol 2009; 88:221-227.
35. Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005; 105:2527-2534. (Pubitemid 40387055)
36. Recher C, Dos Santos C, Demur C, Payrastre B. mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 2005; 4:1540-1549.
37. Mateo-Lozano S, Gokhale PC, Soldatenkov VA, Dritschilo A, Tirado OM, Notario V. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma. Clin Cancer Res 2006; 12:6781-6790.
38. Piguet AC, Semela D, Keogh A, Wilkens L, Stroka D, Stoupis C. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol 2008; 49:78-87.
39. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F. Anti-tumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 2008; 15:257-266.
40. Plo I, Bettaieb A, Payrastre B, Mansat-De Mas V, Bordier C, Rousse A, et al. The phosphoinositide 3-kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukemia cell lines. FEBS Lett 1999; 452:150-154.
41. Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 1995; 55:1982-1988.
42. O'Gorman DM, McKenna SL, McGahon AJ, Knox KA, Cotter TG. Sensitisation of HL-60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals. Leukemia 2000; 14:602-611.
43. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2003; 2:222-232.
44. Memmott RM, Dennis PA. Akt-dependent and-independent mechanisms of mTOR regulation in cancer. Cell Signal 2009; 21:656-664.
45. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005; 120:747-759.
46. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Pérez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 2007; 7:3-18.
47. Sedletska Y, Giraud-Panis MJ, Malinge JM. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents 2005; 5:251-265.
48. Manic S, Gatti L, Carenini N, Fumagalli G, Zunino F, Perego P. Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 2003; 3:21-29.
49. Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 2000; 57:1229-1235.